Lagos — An HIV vaccine candidate trialed in Sub-Saharan Africa offers no substantial protection against HIV infection among young women, the study organisers say.
According to a statement released this week (31 August) by Johnson & Johnson (J&J), the US drugmaker that produced the HIV vaccine candidate, the mid-stage Imbokodo study began in 2017, reached full enrollment in 2019 and completed vaccinations on 30 June 2020.
...
AllAfrica Subscription Content
You must be an allAfrica.com subscriber for full access to certain content.
You have selected an article from the AllAfrica archive, which requires a subscription. You can subscribe by visiting our subscription page. Or for more information about becoming a subscriber, you can read our subscription and contribution overview.
For information about our premium subscription services:
You can also freely access - without a subscription - hundreds of today's top Africa stories and thousands of recent news articles from our home page »
Already a subscriber? Sign in for full access to article